Author: Ravi Shankar

• Framework agreement underpins phased deployment across Liberty Global operating companies
• AI-powered customer interactions will create simpler, faster and more effective customer journeys allowing care teams to focus on more complex tasks

DENVER and LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) —

Liberty Global today announced a three-year strategic partnership with Sierra, a conversational AI platform that is redefining how businesses interact with their customers, to support the rollout of its technology across Liberty Global operating companies. Liberty Global is accelerating the use of AI across its businesses to make customer interactions easier, more intuitive and more effective.

The framework partnership agreement provides Liberty Global’s businesses with a common approach to deploy AI agents capable of engaging customers in natural language, across chat, voice and text.

By enabling AI agents to handle routine and increasingly complex interactions, the partnership will also allow customer-care teams to focus more of their time on situations requiring human judgement and deep expertise.

Liberty Global will deploy Sierra across its approximately 80m fixed and mobile connections in Europe through a phased programme, with implementation already started and the use cases and channel mix tailored to the requirements of individual markets, brands and customers.

Founded by Bret Taylor, former Co-CEO of Salesforce and Chairman of OpenAI, and Clay Bavor, former Google executive, Sierra has emerged as the leading company in the customer experience AI space. The company was valued at $15bn in its latest funding round in May 2026 and its platform is already used by more than 40% of the top 50 companies in the Fortune 500 and one in three of the leading banks, powering billions of customer interactions in industries such as financial services, retail, telecommunications, healthcare and more.

Mike Fries, Liberty Global Chairman and CEO, said: “Sierra has built a game-changing platform that we are excited to deploy across our footprint. By combining Sierra’s technology and deployment expertise with the deep knowledge of our local teams, we will deliver better customer experience across our group by making customer journeys simpler, faster and more effective.”

Bret Taylor, Sierra CEO and Co-Founder, said: “We’re excited to partner with Liberty Global — a pioneer in applied AI and a telecommunications leader with significant scale, expertise and a deep understanding of European customers. This partnership is a strong vote of confidence in Sierra’s ability to improve customer experiences, reduce the burden on support teams and grow revenue. We look forward to working with Mike and the team as we roll out agents across Liberty Global’s companies.”

ABOUT LIBERTY GLOBAL

Liberty Global Ltd. (Nasdaq: LBTYA, LBTYB, LBTYK) delivers long-term shareholder value through the strategic management of two complementary platforms: Liberty Telecom and Liberty Growth.

Liberty Telecom is a world leader in converged broadband, video and mobile communications, providing approximately 80 million fixed and mobile connections across Europe through advanced fiber and 5G networks that empower customers and strengthen national economies. The business generates aggregate revenue of $22 billion, including approximately $18 billion from nonconsolidated joint ventures and $4 billion from consolidated operations.

Liberty Growth invests in scalable businesses across the technology, media, sports and infrastructure sectors, with a portfolio of roughly 70 companies and funds valued at $3.4billion.*

Together, these platforms reflect Liberty Global’s focus on operating, enabling and investing in businesses with strong strategic fit and the potential to deliver sustainable long-term returns.

*As independently valued as of December 31, 2025.

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to business strategies, future growth prospects; valuation expectations and other information and statements that are not historical fact. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. These risks and uncertainties include events that are outside of Liberty Global’s control. These forward-looking statements speak only as of the date of this release. Liberty Global expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

ABOUT SIERRA

Sierra is the leading conversational AI platform, helping businesses create better customer experiences and stronger business outcomes with AI. Launched in February 2024, Sierra has become one of the fastest growing enterprise software companies of all time — reaching over $100M in ARR in just 7 quarters. Agents built on Sierra can do everything from product discovery to returns, refinancing loads and originating mortgages to preventing subscribers from churning.

CONTACT: Investor Relations
Michael Bishop +44 20 8483 6246

Corporate Communications
Pádraig McGarrigle +44 7474 736967
mediarelations@libertyglobal.com

DOVER, USA, Sept. 23, 2026 (GLOBE NEWSWIRE) — E-Power Inc. (“E-Power,” the “Company,” “we” or “our”) (NASDAQ: EPOW), a provider of advanced battery materials and AI Data Center (AIDC) microgrid solutions, today announced that its indirectly wholly-owned subsidiary, Shandong Sunrise Technology Co., Ltd. (“Shandong Sunrise”), has completed the equipment process design and technical consulting services required under its turnkey contract with Shandong Fusion New Material Co., Ltd. (the “Customer”), announced on August 27, 2026 (the “Contract”), and has received the associated payment of RMB 61,825,140 (approximately US$9.2 million) in full.

The technical services represent the first completed phase of the Contract, which has a total value of RMB 343,473,000 (approximately US$51.2 million) and was awarded to Shandong Sunrise in June 2026. The work was performed by the Company’s engineering team.

Completed Contract Scope and Consideration

• Artificial Graphite Anode Line: Full process and equipment design and technical consulting services for a fully automated production line with a designed capacity of 20,000 tons per year — RMB 37,474,515 (approximately US$5.6 million).
• Silicon-Carbon Anode Line: Full process and equipment design and technical consulting services for a production line with a designed capacity of 1,000 tons per year — RMB 24,350,625 (approximately US$3.6 million).
• Total: RMB 61,825,140 (approximately US$9.2 million), representing approximately 18% of the total Contract value, received in full.

From Award to Execution

The completion of this work represents the first component of the Contract, with the related services delivered and payment received in full. The remaining obligations required under the Contract include equipment manufacture and phased delivery, on-site installation and commissioning, operator training, testing and environmental auxiliary equipment, spare parts, technical documentation and a 12-month warranty period, culminating in load-bearing trial production and final acceptance at the Customer’s advanced electronic materials project in the Laiwu District of Jinan, Shandong Province, China.

The engagement reflects the Company’s strategy of commercializing process know-how developed through the construction and operation of anode facilities through its joint venture and subsidiaries. The design work delivered under this phase covers both conventional artificial graphite production and silicon-carbon anode material, a next-generation material for high-energy-density batteries.

“The completion of this Contract phase and collection of the full payment is the kind of milestone we said we would report,” said Mr. Haiping Hu, the founder, CEO and Chairman of E-Power Inc. “We believe that design and process engineering is where our accumulated know-how is most directly monetized, and that the completion of this phase provides both our Customer and our shareholders with a concrete measure of execution. We intend to continue to provide updates as the equipment phases of the Contract progress.”

About E-Power Inc.

E-Power Inc., through its subsidiaries, joint venture and variable interest entity structure, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. Through its joint venture, the Company operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant’s competitive production costs and reduced environmental impact in the production of graphite anode material. Mr. Haiping Hu, the founder, CEO and Chairman of the Company, has been a pioneer in the graphite anode industry since 1999. The Company’s management team is composed of experts with years of experience and successful track records in the graphite anode industry. For further information, please visit the Company’s website at www.sunrisenewenergy.com.

Forward-looking statement

Certain statements in this press release regarding the Company’s future expectations, plans and prospects constitute forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about plans, goals, objectives, strategies, future events, expected results, assumptions, the completion of the remaining phases of the Contract, the timing of equipment manufacture, delivery, installation and acceptance, and any statements that are not historical facts. Words such as “may,” “will,” “plan,” “anticipate,” “should,” “believe,” “expect,” “estimate,” and similar words, shall be regarded as forward-looking statements. Due to various factors, the actual results may differ materially from the historical results or from those expressed or implied by these forward-looking statements. These factors include, but are not limited to, the Company’s strategic objectives, the Company’s future plans, market demand and user acceptance of the Company’s products or services, the Company’s ability to complete the remaining phases of the Contract and the timing of equipment manufacture, delivery, installation, commissioning and final acceptance, technological updates, economic trends, the Company’s reputation and brand, the impact of industry competition, relevant policies and regulations, China’s macroeconomic conditions, international market conditions, and other related risks and assumptions. In view of the above and other related reasons, we advise investors not to place undue reliance on these forward-looking statements, and we urge investors to visit the website of the United States Securities and Exchange Commission to review the Company’s filings for other factors that may affect the Company’s future operating results. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

For more information, please contact:

The Company: IR Department
Email: IR@sunrisenewenergy.com
Phone: +1 4084890472

This phase 2b/3, double-blind trial of oral Xanamem in 247 participants with mild to moderate Alzheimer’s disease and elevated pTau181 evaluates the potential benefit of targeting excess cortisol in the brain over a 36-week treatment period

SYDNEY, Australia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Actinogen Medical Limited (ASX: ACW) today announces that, following the final participant visit on 22 September in the USA, topline results for the XanaMIA phase 2b/3 Alzheimer’s disease (AD) clinical trial remain on track for November this year. This is the first Xanamem^® trial to evaluate the potential benefits of tissue cortisol control over a period longer than 12 weeks. Despite recent advances in Alzheimer’s disease treatment, substantial unmet need remains for therapies that can deliver meaningful clinical benefit, are easier to administer, and act through additional biological pathways.

Xanamem (emestedastat) is a promising oral enzyme inhibitor designed to control elevated levels of the “stress hormone” cortisol in the brain, which are associated with the onset and progression of AD. Elevated cortisol is also associated with ApoE4, the primary genetic risk factor for AD. Xanamem is a potent and highly selective enzyme inhibitor of 11β-HSD1, the cellular enzyme responsible for cortisol synthesis in tissues other than the adrenal glands, which is strongly expressed in regions of the brain important for cognition, including memory and executive function.

The XanaMIA trial is a randomized (1:1), double-blind, placebo-controlled phase 2b/3 trial evaluating Xanamem 10 mg versus placebo over 36 weeks, with a four-week follow up period. Participants are then eligible to enrol in an open-label extension phase and receive Xanamem 10 mg. The trial has now completed all patient visits, with 247 participants enrolled across Australia (45%) and the United States (55%).

Using elevated plasma pTau181 to select participants is a key feature of the trial. It has high validity for identifying AD in this population and is highly efficient compared with more complex methods such as amyloid brain scans or cerebrospinal fluid biomarkers. Elevated pTau181 also selects for participants with a more progressive disease course, increasing the trial’s power to detect a treatment effect for Xanamem and replicating the diagnostic profile of the phase 2a patient population where a large treatment benefit for Xanamem was observed (Taylor et al. 2024).

Enrolled participants had baseline clinical, genetic and laboratory characteristics similar to those reported in other trials of patients with mild to moderate AD:

1. Average age of 75 years
2. 49% female
3. 66% ApoE4 carriers (main AD genetic risk factor)
4. Mean (SD) pTau181 2.6 (1.3) pg/mL
5. Mean (SD) CDR-SB 4.3 (2.0) points.

Topline results from the trial are expected in November.

Dr Dana Hilt, the Company’s CMO commented:

“Xanamem is a unique oral therapy with the potential to become a transformational treatment option for patients and their families living with Alzheimer’s disease. Our key focus is to finalise high-quality data from the XanaMIA pivotal trial for release in November while planning streamlined pathways to the fastest possible regulatory approvals for Xanamem.” 

^® Xanamem is a registered trademark of Actinogen Medical Limited

About Actinogen Medical 
Actinogen Medical (ACW) is an ASX-listed, biotechnology company in the late clinical stages of development for Xanamem® (emestedastat), its novel oral therapy for Alzheimer’s disease and depression. The Company is based in Sydney, Australia with operations and clinical trials in Australia and the US. Xanamem has been studied in eight clinical trials with more than 500 people treated to date and has a promising safety and efficacy profile. ACW’s ongoing clinical trial, XanaMIA, is a phase 2b/3 pivotal trial of 247 participants with mild to moderate Alzheimer’s disease, treated for 36 weeks with Xanamem 10 mg or placebo, followed by an open-label extension phase with active Xanamem 10 mg for completing participants. In January 2026 an Independent DMC conducted an interim analysis of safety and efficacy futility and recommended the trial proceed to completion. The trial is now fully enrolled and will report topline, final results from the randomized phase in November this year.

About Xanamem (emestedastat)
Xanamem’s novel mechanism of action is to control the level of cortisol in the important areas of the brain through the inhibition of the cortisol synthesis enzyme, 11β-HSD1, without blocking normal production of cortisol by the adrenal glands. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of brain cortisol control in regions where 11β-HSD1 is highly expressed such as the hippocampus. Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Elevated cortisol is also associated with depressive symptoms. Xanamem has demonstrated excellent brain target engagement and in human trials has shown potential to slow progression of Alzheimer’s disease and improve depressive symptoms in patients with moderately severe depression. To view Xanamem’s two-minute Mechanism of Action animation, click here.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer
This announcement and attachments may contain certain “forward-looking statements” that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered “at-risk statements” – not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realized.

CONTACT: Dr. Steven Gourlay
CEO & Managing Director
E. steven.gourlay@actinogen.com.au

Investors
Will Souter
Investor Relations
E. will.souter@actinogen.com.au

Media
George Hazim
Media & Public Affairs Australia
E: georgehazim@mediaaffairs.com.au 

Strengthens Global Intellectual Property Estate for Annamycin’s Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity

HOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company’s global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin technology.

The newly issued patent supports Moleculin’s strategy of building a robust worldwide intellectual property estate around Annamycin, the Company’s highly efficacious and well tolerated anthracycline currently being evaluated in the pivotal MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML), while also reinforcing the platform’s broader potential across additional oncology indications.

Unlike conventional anthracyclines, Annamycin was specifically engineered to avoid multidrug resistance mechanisms while demonstrating the ability to penetrate tissues that are traditionally difficult to treat, including the lungs. The patented liposomal formulation is designed to enhance delivery of Annamycin to pulmonary tumors and metastatic disease, potentially expanding future development opportunities beyond hematologic malignancies.

“This newly granted Mexican patent represents another important milestone in strengthening the global intellectual property foundation supporting our Annamycin platform,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “As we continue advancing the MIRACLE trial toward important clinical milestones, we are simultaneously protecting the long-term value of Annamycin through an expanding international patent portfolio. Strong intellectual property is a critical component of building lasting shareholder value, and this patent further reinforces the commercial potential of our proprietary technology platform well into the next decade.”

The Mexican patent complements Moleculin’s growing international patent estate protecting Annamycin and its proprietary formulations across multiple jurisdictions. The patent remains in force until November 23, 2040, providing long-term exclusivity for the covered technology.

The announcement comes as Moleculin continues to execute on multiple value-driving initiatives centered on Annamycin. The Company’s pivotal MIRACLE trial is evaluating Annamycin in combination with high-dose cytarabine for patients with relapsed or refractory AML, an area of significant unmet medical need. In parallel, Moleculin continues to broaden the scientific and commercial foundation supporting future opportunities for the Annamycin platform through ongoing innovation and strategic intellectual property expansion.

As Moleculin advances toward additional clinical milestones, management believes its combination of differentiated science, advancing late-stage development, and expanding global patent protection positions the Company to create meaningful long-term value for patients and shareholders alike.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding the strength and enforceability of the Company’s intellectual property portfolio, the scope of patent protection and long-term exclusivity provided by issued patents, the commercial potential of the Company’s proprietary technology, and the potential efficacy and safety of Annamycin and AnnAraC in R/R AML . Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

James Heckman, CEO of Roundtable (Nasdaq: RTB); John D’Agostino, Head of Institutional Strategy at Coinbase; and Eyal Hertzog, inventor of DeFi and co-founder of RTB

Instant settlement in USDC for journalists, on RTB’s decentralized, AI-reporting smart wallet network, connected to Roundtable’s “Media Liquidity Pool” and secured by Coinbase, empowering decentralized, independent journalism Platform unveiled in London.

LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) — Roundtable (Nasdaq: RTB), an AI/DeFi-powered Enterprise MediaOS and marketplace, today announced that their DeFi/AI reporting and payment platform is live, integrated with Roundtable’s “Media Liquidity Pool,” and settling advertising payments in real time with USDC through smart wallets linked to journalists’ Coinbase accounts.

The platform combines Coinbase’s USDC payment infrastructure Coinbase accounts with RTB’s enterprise-level Web3 mediaOS and AI-driven smart wallet system. It requires no human intermediary, giving publishers and journalists full autonomy, transparency, and control of their IP, now rewarded in real time, while creating and connecting with their audience.

$100 Million ecosystem 

Roundtable recently announced a ten-year contract to migrate 21 major media brands, hundreds of journalists, and nearly 100 million viewers consuming $100 million in advertising from a Web1 platform with manual fiat currency payments that can take 90 days or more, to “net-zero” on Roundtable’s Web3, AI-driven Media OS and DeFi payment platform. Already live in the U.S. with hundreds of journalists, the platform tracks and clears trillions of AI-monitored bids through dynamic DeFi smart wallets.

“USDC is no longer an abstract promise for commercial use. We are embracing DeFi and crypto banking, starting with journalists being fairly rewarded for value already created,” said James Heckman, Founder and CEO of Roundtable. “Coinbase provides the institutional infrastructure to finance and bank our enterprise customers, while Roundtable’s AI/DeFi technology delivers immutability, transparency and accuracy. Together, we demonstrate how decentralized finance and USDC can strengthen journalism and publishers.”

“Of the many ways blockchain and cryptocurrency are upgrading the financial system, few use cases are as compelling as transforming payment cycles for independent journalists. Coinbase is proud to support Roundtable’s mission to revolutionize ad sales and help the next generation of journalists thrive,” said John D’Agostino, Head of Institutional Strategy at Coinbase.

Global Media Coalition – European Discussions

Following the North American, 21 premium brand, $100 million consumer announcement, the MediaOS and Coinbase/Roundtable integration is being unveiled to the British press this week, led by former UK Prime Minister and foreign secretary, Liz Truss, as Roundtable CEO James Heckman joins Truss in London to offer major media brands the platform at no cost, as part of a premium media coalition for European press. On September 18th, Truss joined the Board of Directors of Roundtable.

“Great Britain has one of the world’s richest traditions of independent journalism and most respected media brands. Yet professional media faces unprecedented technological and economic challenges, particularly from AI and global technology platforms,” said Truss. “I’m honored to join Roundtable’s distinguished technology leaders and senior media executives, offering the highest level of technology – purpose-built for human-led, professional media.”

RTB Shares Now Trading on Coinbase

Coinbase is bridging traditional finance and crypto across banking, payroll, credit and trading. Roundtable is leveraging the full ecosystem, including RTB’s Nasdaq-listed shares now trading on Coinbase as of today’s opening.

About Roundtable (RTB Digital, Inc.)

Roundtable (NASDAQ: RTB) is an AI/DeFi-powered Enterprise Media Operating System, integrating distribution, publishing, monetization, community, syndication and DeFi payment operations, powering professional and major media brands. The Web3 platform was developed over years by digital pioneers and co-founders Eyal Hertzog and James Heckman.

For more information, visit rtb.io.

About Coinbase

Coinbase (Nasdaq: COIN) is on a mission to increase economic freedom in the world. The most trusted crypto platform, Coinbase stores more digital assets than any other company and is building the everything exchange — one place to access crypto, equities, derivatives, prediction markets, and more. Coinbase serves consumers through its suite of financial apps, institutions through Coinbase Prime, and developers through the Coinbase Developer Platform. Coinbase’s full-stack platform was purpose-built to power the future of finance: secure custody, deep exchange liquidity, stablecoin infrastructure, and global settlement rails — all built on a decade-plus foundation of security and compliance.

Cautionary Note Regarding Forward-Looking Statements

This press release includes information that constitutes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such forward-looking statements include statements that are characterized by future or conditional words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate,” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such forward-looking statements include statements regarding the accretive transactions undertaken in 2026 and future operations and revenues of the company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results to differ materially from those expressed in or contemplated by the forward-looking statements, such as the company being able to maintain its listing on Nasdaq for the common stock, having sufficient capital for its acquisitions, operations and business expansion, and developing its business and capturing users for its services. Annualized and longer period revenue and business estimates are subject to the effect of macroeconomic events, to industry changes, to competitive forces, to client development and retention, to capital availability, and to many other operational factors; therefore, any financial forecasts offered by the Company must take into account the fact that the underlying assumptions may significantly change over time and projected results may substantively increase or decrease. Other risk factors affecting the Company are discussed in detail in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

Investor Relations Contact: ir@roundtable.io

Public Relations Contact: press@roundtable.io

Proposed initiative would seek to create an issuer-authorized, blockchain-based representation of Myseum.AI common stock while preserving traditional shareholder rights

NEW BRUNSWICK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — Myseum.AI, Inc. (Nasdaq: MYSE) (“Myseum.AI” or the “Company”), a privacy-first agentic AI and social media technology company, today announced that it intends to apply to tokenize its Nasdaq-listed common stock through one or more qualified digital-asset securities platforms.

The planned application follows significant regulatory developments supporting the introduction of blockchain-based representations of publicly traded equities in the United States. Myseum.AI intends to evaluate an issuer-authorized structure in which tokenized Myseum.AI shares would represent the Company’s actual registered common stock, not synthetic exposure, and would be designed to preserve the economic, voting and other ownership rights associated with traditional Myseum.AI shares. The announcement does not constitute the issuance of a new security, a change in the Company’s existing capital structure or an offer to sell securities. Myseum.AI’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “MYSE.” Existing shareholders are not required to take any action at this time.

If approved and successfully implemented, tokenization could allow eligible investors to hold and transfer a digital representation of Myseum.AI common stock using blockchain infrastructure, subject to applicable securities laws, trading-platform requirements and geographic restrictions.

Potential benefits under evaluation include:

• Expanded access to Myseum.AI shares through digital native investment platforms.
• Greater transparency through blockchain-based ownership records.
• More efficient trade settlement and share transfers.
• Potential access to extended hours or continuous trading environments where legally permitted.
• Improved interoperability between traditional securities and regulated digital-asset infrastructure.
• Broader engagement with a new generation of global and digitally native investors.

“Tokenization has the potential to fundamentally modernize how public-company shares are held, transferred and accessed,” said Darin Myman, Chief Executive Officer of Myseum.AI. “We believe Myseum.AI has an opportunity to move decisively as regulated capital markets begin adopting blockchain infrastructure.”

“Our objective is not to create a synthetic instrument that merely tracks Myseum.AI’s market price,” Myman continued. “We intend to explore an issuer-supported structure designed to represent actual ownership of Myseum.AI common stock and preserve the rights of our shareholders. We believe this distinction is essential to building a transparent, compliant and credible tokenized-equity program.”

The Company plans to begin discussions with regulated tokenization platforms, broker-dealers, transfer agents, custodians and other digital-securities infrastructure providers. The Company will evaluate potential blockchain networks and service providers based on regulatory compliance, cybersecurity, investor protection, market accessibility, scalability and compatibility with Myseums.ai’s existing Nasdaq listing.

Any tokenization would be subject to completion of the Company’s evaluation process, acceptance by a qualified provider or trading platform, applicable regulatory and exchange requirements, and the negotiation of definitive agreements. There can be no assurance that the application will be accepted or that tokenized trading of Myseum.AI common stock will ultimately become available.

About Myseum.AI, Inc.

Myseum.AI (formerly DatChat, Inc.) is a privacy-focused AI and social media technology company developing innovative platforms for secure digital sharing and storage. Its flagship platform, Picture Party, is a next-generation patented instant social networking experience designed to make sharing photos easier, more fun, and more private. The platform enables users to create curated albums, build encrypted galleries with controlled access, personalize their content feeds, and organize collections within a broader digital ecosystem. Picture Party by Myseum.AI is currently available at the iOS App Store and Google Play, with a desktop version expected later this year. For more information, visit myseum.com.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact
ir@datchats.com
732-374-3529

ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer.

“Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the world. He knows firsthand what it takes to translate strategy into growth,” said Maher Masoud, President and Chief Executive Officer. “I am confident that Sidharth’s expertise will support MaxCyte’s next chapter of growth.”

Mr. Kapileshwar joins MaxCyte from Danaher Corporation, where he most recently served as Vice President of Innovation for the company’s Life Sciences Platform, leading enterprise-wide innovation programs. Over nearly 25 years, he has held corporate development, strategy, innovation, and M&A leadership roles at global life sciences and technology companies, including GE Healthcare, Beckman Coulter, and Halma plc. Mr. Kapileshwar holds a Master of Science in Engineering from The Ohio State University, an MBA from the University of Chicago Booth School of Business, and a Bachelor of Technology in Engineering from the Indian Institute of Technology Bombay.

“MaxCyte has been an early pioneer in applying flow electroporation at clinical and commercial scale for cell and gene therapies, and its technologies are foundational to where the field is headed. That’s exactly the kind of opportunity I want to help build at MaxCyte,” said Sidharth Kapileshwar. “I’ve spent my career helping large, global organizations sharpen their strategies and execute their next phase of growth, and I’m excited to bring that same momentum to MaxCyte.”

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

MaxCyte Contacts:

Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — SPARC AI Inc. (CSE: SPAI; OTCQB: SPAIF; Frankfurt: 5OV0) (“SPARC AI” or the “Company”), a defense technology company delivering positioning in GPS-denied environments, today announced the completion of a three-week customer tour of Ukraine following the International Defence Industry Exhibition (MSPO) in Kielce, Poland, where the Company launched Overwatch Patrol.

The tour opened with a series of private events attended by more than a dozen drone OEMs and operators, where SPARC AI showcased the Overwatch Positioning Network and launched Overwatch Intelligence. Overwatch Intelligence is a premium module for intelligence, surveillance and reconnaissance (ISR) missions in GPS-denied conditions. It turns what a drone sees into georeferenced intelligence, allowing operators to extract target coordinates from live or recorded imagery with no GPS on the aircraft. Operators can click on any pixel in an image to obtain the location coordinates of a target.

The team then travelled to several polygons (military test ranges) for live demonstrations with drone manufacturers before heading east to within 17 km of the front line. There, Overwatch was integrated on site into a large quadcopter and deployed in a GPS-jammed environment, where the team completed a series of flights obtaining aircraft position and target coordinates without satellite navigation. In one demonstration, the aircraft recorded the precise location of a pole more than 600 metres away with no GPS, no laser rangefinder and no additional hardware on the aircraft.

The tour also demonstrated the speed of the Overwatch Positioning Network under battlefield conditions. Telemetry from the drone was sent to Overwatch and latitude and longitude were returned in milliseconds, confirming the service can deliver positioning in a contested environment with no compute or software on the aircraft. No telemetry or position data is stored by Overwatch.

Overwatch Patrol, the Company’s dismounted positioning service launched at MSPO, was also demonstrated during the tour. In one demonstration under GPS interference, the device’s satellite-derived position placed the user several kilometres from their actual location, while Overwatch Patrol displayed the correct position with no GPS and no additional hardware.

Ukraine remains the most demanding operating environment in the world for drone technology, and the tour allowed SPARC AI to demonstrate Overwatch to new OEMs and operators flying daily under electronic warfare conditions.

Prior to Poland and Ukraine, the team demonstrated Overwatch in a Western-aligned partner nation in the Middle East under similar GPS-jamming conditions. There, Overwatch successfully obtained the aircraft’s position without satellite navigation and then generated target coordinates through the Overwatch Positioning Network – the same self-locate to target-locate sequence later flown near the front line in Ukraine.

Following these deployments, the Company is engaged with several drone OEMs on existing and new opportunities, with Overwatch proven to operate in highly contested and GPS-jammed environments. These engagements include extending Overwatch’s capability to unmanned ground vehicles (UGVs) and fixed-wing platforms. The Company is also in the process of obtaining a NATO Stock Number (NSN) for Overwatch, which would enable the product to be catalogued and procured through NATO and allied defense supply systems. The Company expects to provide further updates as these engagements progress.

About SPARC AI Inc.
SPARC AI is a defense technology company solving navigation in GNSS-denied environments. Its flagship product, Overwatch, is a platform that ingests telemetry from drones and other moving platforms and returns absolute latitude and longitude — no onboard software, no edge hardware, and no reliance on GPS. Delivered as a stateless service, Overwatch gives commercial and defense operators dependable positioning wherever satellite signals are jammed, spoofed, or unavailable.

Cautionary Statement Regarding Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws and may also constitute “forward-looking statements” within the meaning of United States securities laws (collectively, “forward-looking statements”). Forward-looking statements in this release include, but are not limited to, statements regarding the use of proceeds from the completed financing, the Company’s future, R&D programs, development activities, and the potential of its technology. Forward-looking statements are based on the current expectations, estimates, beliefs and assumptions of management as of the date hereof. Such statements are subject to several known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the use of proceeds, market conditions, competition, development activities, pricing, and general economic conditions. Although the Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information contact:
SPARC AI Inc.
E-mail: investors@sparcai.com
Web: www.sparcai.com
Tel: (213) 459-3994

Transaction in Own Shares

September 22, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 22 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
22/09/2026	900,000	£ 35.2300	£ 34.4500	£ 34.8883	LSE	GBP
22/09/2026	150,000	£ 35.1650	£ 34.4600	£ 34.8434	Chi-X (CXE)	GBP
22/09/2026	–	–	–	–	BATS (BXE)	GBP
22/09/2026	500,000	€ 41.1550	€ 40.2250	€ 40.7185	XAMS	EUR
22/09/2026	–	–	–	–	CBOE DXE	EUR
22/09/2026	–	–	–	–	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

• 20260922_Shell RNS – full version

New solution enhances multi-channel candidate sourcing, recruiting workflow automation, candidate matching support, and hiring expertise to help businesses hire faster while maintaining decision-making authority 

• Paychex launches AI-agent platform built for front-line workers to help customers hire more quickly and effectively
• Solution is available as both a standalone offering and integrated within Paychex’s HCM platforms
• WISE Hire is accessible through WISE, the company’s AI engine spanning embedded intelligence, personal assistants, and AI agents

ROCHESTER, N.Y., Sept. 23, 2026 (GLOBE NEWSWIRE) — Paychex (Nasdaq: PAYX), a leading provider of expert-enabled HR, payroll, and benefits, today introduced WISE Hire, an AI-native recruiting solution that helps businesses find and hire qualified talent 4x faster on average. Available standalone or integrated within Paychex’s HCM platforms, WISE Hire combines AI agents for digital candidate sourcing, recruiting, and hiring coaching. The result is an automated experience that maintains strong governance, human-in-the-loop oversight, and customer control of hiring decisions.

Paychex research consistently shows attracting and recruiting talent is one of the most significant challenges a business faces – and business leaders spend more than one-third of their time on administrative hiring tasks.

“Offering solutions that help our customers solve some of their most pressing challenges, such as recruiting and hiring, is core to our product strategy,” said Ryan Bergstrom, Chief Product and Technology Officer at Paychex. “WISE Hire expands on our existing capabilities, empowering businesses to fill positions faster by automating routine hiring tasks while keeping people at the center of every hiring decision.”

Expanding WISE with Embedded AI Recruiting Automation and Expertise
WISE Hire will help businesses fill vacancies quickly and effectively by embedding recruiting workflow automation, candidate matching support, and hiring expertise in WISE, Paychex’s AI engine across its HCM platforms — SurePayroll, Paychex Flex^®, and Paycor^®. Whether used integrated or standalone, the AI-powered technology is designed to automate routine workflows such as sourcing, screening, coordination, and scheduling, while a patented candidate-matching technology and network of hiring coaches pairs automation with human expertise.

Broad Candidate Reach, Smarter Recruiting Workflows, and Human-Led Hiring Decisions
WISE Hire can also access industry-leading worker acquisition channels such as Google for Jobs, Meta’s local jobs marketplace, and ChatGPT to enhance candidate sourcing. Employers retain responsibility for evaluating candidates and making hiring decisions, with human oversight incorporated throughout the recruiting workflow. WISE Hire will help new and existing customers attract, screen, and engage candidates more efficiently and effectively, while maintaining human oversight and decision-making authority.

Advancing the Future of Hiring Through Intelligent Workforce Technology
While WISE Hire is integrated across Paychex’s HCM platforms, the solution is also available standalone. The latest demonstration of the company’s ongoing commitment to delivering innovative, AI-driven solutions to help customers solve workforce challenges and achieve better business outcomes. Combining WISE intelligence with AI-powered hiring capabilities, Paychex is making it easier for businesses of all sizes to find, hire, and retain the right talent faster.

To learn more about WISE Hire, along with Paychex’s full suite of expert-enabled technology and advisory solutions, visit the Paychex booth (#4227) at the HR Technology Conference & Expo at Mandalay Bay in Las Vegas, Oct. 20-22, 2026.

About Paychex
Paychex, Inc. (Nasdaq: PAYX) provides a comprehensive suite of expert-enabled technology and advisory solutions that help businesses manage HR, payroll, and benefits. Serving approximately 840,000 customers and paying 1 in 11 U.S. private sector workers, Paychex combines scale, trusted expertise, and innovation to help businesses succeed. Built on more than 50 years of workforce experience and one of the industry’s largest proprietary HR datasets, Paychex’s WISE agentic AI engine embeds intelligence directly into workflows to improve productivity, enhance decision-making, and deliver better outcomes. Learn more at paychex.com.

Media Contact
Tracy Volkmann
Manager, Public Relations
Paychex, Inc.
(585) 657-7336
tvolkmann@paychex.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/805fb418-499b-4ce9-bffa-42d4f10dad14